Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media

Pediatric Infectious Disease Journal

Volumn 25, Issue 11, 2006, Pages 1001-1007

  Cohen, Robert ^a   Levy, Corinne ^b   De La Rocque, France ^b   Gelbert, Nathalie ^c   Wollner, Alain ^b   Fritzell, Bernard ^d   Bonnet, Eric ^d   Tetelboum, Robert ^d   Varon, Emmanuelle ^e  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b ACTIV Association Clinique et Thérapeutique Infantile du Val de Marne   (France)

^c AFPA Association Francaise de Pediatrie Ambulatoire   (France)

^d Early Development and Clinical Pharmacology   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Acute otitis media; Pneumococcal conjugate vaccine; Pneumococcal nasopharyngeal carriage; Reduction of antibiotic use

Indexed keywords

ANTIBIOTIC AGENT; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; FRANCE; HUMAN; IMMUNIZATION; INFANT; MALE; MEDICAL SPECIALIST; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CARRIER STATE; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; NASOPHARYNX; OTITIS MEDIA; PENICILLIN RESISTANCE; PENICILLINS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 33749432540     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000243163.85163.a8     Document Type: Article

References (38)

1. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet. 2001;357:1851-1853.
2. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579-587.
3. Klugman KP. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect Dis. 2001; 1:85-91.
4. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-1924.
5. Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185:927-936.
6. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis. 1996;174:1271-1278.
7. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J. 1997;16:1060-1064.
8. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999;180:1171-1176.
9. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet. 1996;348:271-272.
10. Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J. 2003;22:532-540.
11. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J. 2003;22:524-532.
12. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine. 2003;21:1815-1825.
13. Temime L, Guillemot D, Boelle PY. Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance. Antimicrob Agents Chemother. 2004;48:2206-2213.
14. Cohen R, Gaudelus J, Reinert P, Levy C. Observatory of Pediatric Practice in Vaccinology (ObVac): use of Prevenar®. Méd Enfance. 2005;25:299-302.
15. Kouchner B, National plan to promote prudent antibiotic use. Available at: http://www.sante.gouv.fr/htm/actu/antibio/index.htm.2001.
16. Guillemot D. Evolution of antibiotic consumption in ambulatory practice 2002-2004. Available at: http://www.ameli.fr/174/DOC/1564/ dp.html.2004.
17. Finkelstein JA, Huang SS, Daniel J, et al. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics. 2003;112:862-869.
18. Syrjanen RK, Kilpi TM, Kaijalainen TH, Herva EE, Takala AK. Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. J Infect Dis. 2001;184:451-459.
19. Paradise JL. On classifying otitis media as suppurative or nonsuppurative, with a suggested clinical schema. J Pediatr. 1987;111:948-951.
20. Howie VM, Ploussard JH, Lester RL Jr. Otitis media: a clinical and bacteriological correlation. Pediatrics. 1970;45:29-35.
21. Palmu AA, Herva E, Savolainen H, Karma P, Makela PH, Kilpi TM. Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis. 2004;38:234-242.
22. Rodriguez WJ, Schwartz RH. Streptococcus pneumoniae causes otitis media with higher fever and more redness of tympanic membranes than Haemophilus influenzae or Moraxella catarrhalis. Pediatr Infect Dis J. 1999;18:942-944.
23. Bingen E, Cohen R, Jourenkova N, Gehanno P. Epidemiologic study of conjunctivitis-otitis syndrome. Pediatr Infect Dis J. 2005;24:731-732.
24. Bodor FF. Conjunctivitis-otitis syndrome. Pediatrics. 1982;69:695-698.
25. Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis. 1980;142:923-933.
26. Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis. 2004;39:930-938.
27. Moore MR, Hyde TB, Hennessy TW, et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis. 2004;190:2031-2038.
28. Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J. 2004;23:1015-1022.
29. Veenhoven RH, Bogaert D, Schilder AG, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin Infect Dis. 2004;39:911-919.
30. Cohen R, Levy C, Hentgen V, et al. Relationship between clinical signs and symptoms and nasopharyngeal flora in acute otitis media. Clin Microbiol Infect. 2006;12:679-682.
31. Marchisio P, Esposito S, Schito GC, Marchese A, Cavagna R, Principi N. Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children: implications for the use of heptavalent pneumococcal conjugate vaccine. Emerg Infect Dis. 2002;8:479-484.
32. Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Reed KD, Schwartz B. A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children. Pediatrics. 2001;108:575-583.
33. Hennessy TW, Petersen KM, Bruden D, et al. Changes in antibioticprescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: a controlled intervention trial in rural Alaska. Clin Infect Dis. 2002;34:1543-1550.
34. Talbot TR, Poehling KA, Hartert TV, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2004;39:641-648.
35. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
36. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis. 2005;41:139-148.
37. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics. 2005;116:e408-413.
38. Porat N, Arguedas A, Spratt BG, et al. Emergence of penicillin- nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J Infect Dis. 2004;190:2154-2161.